Highest Evidence-Based Pyridostigmine IR Doses Per Single Dose
The highest evidence-based single dose of immediate-release pyridostigmine studied is 60 mg, which is the standard dose used in clinical trials for myasthenia gravis and orthostatic hypotension. 1, 2, 3
Dosing Evidence by Indication
Myasthenia Gravis
The FDA-approved dosing for immediate-release pyridostigmine in myasthenia gravis uses 60 mg as the standard single dose, with the extended-release 180 mg tablet providing approximately equivalent immediate effect to a 60 mg IR dose 1. The most recent high-quality randomized controlled trial in myasthenia gravis used participants' pre-study pyridostigmine regimens, which were based on this 60 mg standard dosing 3.
Key dosing parameters:
- Standard single dose: 60 mg
- Dosing interval: Every 3-4 hours for immediate-release formulations
- The FDA label does not specify a maximum single dose for IR formulations, only that extended-release tablets (180 mg) should be spaced at least 6 hours apart 1
Orthostatic Hypotension and POTS
Clinical trials consistently used 60 mg as the single dose for orthostatic hypotension:
- The pivotal 2006 randomized controlled trial used 60 mg single doses 2
- The 2020 Canadian Cardiovascular Society guidelines do not specify per-dose limits but reference the standard 60 mg dosing used in trials 4
- A 2025 study evaluating predictors of response used 60 mg single doses 5
Nerve Agent Poisoning
For anticholinesterase poisoning in children, the guideline recommends starting at 0.05 mg/kg (up to initial adult dose of 2-5 mg), with doses doubled and repeated every 10-20 minutes as needed for clinical effect 6. In this emergency context, pyridostigmine doses can reach up to 600 mg daily when treating myasthenic symptoms in the setting of immune-related adverse events 7.
Practical Dosing Algorithm
For routine therapeutic use:
- Start with 60 mg IR as the standard single dose
- Adjust frequency (every 3-4 hours) rather than increasing individual dose size
- For extended-release formulations, 180 mg provides equivalent immediate effect to 60 mg IR but with prolonged duration 1
Important caveats:
- Pharmacokinetic studies show only 7.6% oral bioavailability 8, explaining why relatively large oral doses are needed
- Plasma elimination half-life is approximately 1.5-1.8 hours 8
- Food delays time to peak concentration from 1.7 to 3.2 hours but does not affect bioavailability 8
- Renal impairment requires dose reduction since pyridostigmine is mainly excreted unchanged by the kidney 1
The evidence does not support single doses exceeding 60 mg for IR formulations in standard clinical practice, though emergency situations (nerve agent poisoning) may require different approaches with repeated dosing to achieve atropinization 6, 9.